APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Virus Like Particles

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Virus Like Particles Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchVirus Like Particles Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Virus Like Particles Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Virus Like Particles Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Virus Like Particles Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Virus Like Particles Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Virus Like Particles market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Virus Like Particles include Agilvax, Allergy Therapeutics, ANGANY Genetics, CPL Biologicals, Cytos Biotechnology, GeoVax Labs, Medicago, MedImmune and Novavax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Virus Like Particles market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Virus Like Particles and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Virus Like Particles sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Virus Like Particles market size, projected growth trends, production technologies, key applications, and end-use industries.

Virus Like Particles Segment by Company

Agilvax

Allergy Therapeutics

ANGANY Genetics

CPL Biologicals

Cytos Biotechnology

GeoVax Labs

Medicago

MedImmune

Novavax

Serum Institute of India

TechnoVax

Xiamen Innovax Biotech

GlaxoSmithKline

Merck

Takeda

Virus Like Particles Segment by Type

Hepatitis B Virus

Adeno-Associated Virus

Hepatitis C Virus

HIV

Others

Virus Like Particles Segment by Application

Therapeutic and Imaging Agents

Mycoviruses

Vaccines

Virus Research

Others

Virus Like Particles Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Like Particles market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Virus Like Particles and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Like Particles.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Virus Like Particles market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Virus Like Particles in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Virus Like Particles in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Virus Like Particles Industry Trends Table 2. Virus Like Particles Industry Drivers Table 3. Virus Like Particles Industry Opportunities and Challenges Table 4. Virus Like Particles Industry Restraints Table 5. Global Virus Like Particles Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Virus Like Particles Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Virus Like Particles Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Virus Like Particles Sales Market Share by Manufacturers Table 9. Global Virus Like Particles Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Virus Like Particles Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Virus Like Particles Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Virus Like Particles Manufacturers, Product Type & Application Table 13. Global Virus Like Particles Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Virus Like Particles by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Hepatitis B Virus Table 17. Major Manufacturers of Adeno-Associated Virus Table 18. Major Manufacturers of Hepatitis C Virus Table 19. Major Manufacturers of HIV Table 20. Major Manufacturers of Others Table 21. Global Virus Like Particles Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Virus Like Particles Sales by Type (2021-2026) & (K Units) Table 23. Global Virus Like Particles Sales by Type (2027-2032) & (K Units) Table 24. Global Virus Like Particles Sales Market Share by Type (2021-2026) Table 25. Global Virus Like Particles Sales Market Share by Type (2027-2032) Table 26. Global Virus Like Particles Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Virus Like Particles Revenue by Type (2021-2026) & (K Units) Table 28. Global Virus Like Particles Revenue by Type (2027-2032) & (K Units) Table 29. Global Virus Like Particles Revenue Market Share by Type (2021-2026) Table 30. Global Virus Like Particles Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Therapeutic and Imaging Agents Table 32. Major Manufacturers of Mycoviruses Table 33. Major Manufacturers of Vaccines Table 34. Major Manufacturers of Virus Research Table 35. Major Manufacturers of Others Table 36. Global Virus Like Particles Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Virus Like Particles Sales by Application (2021-2026) & (K Units) Table 38. Global Virus Like Particles Sales by Application (2027-2032) & (K Units) Table 39. Global Virus Like Particles Sales Market Share by Application (2021-2026) Table 40. Global Virus Like Particles Sales Market Share by Application (2027-2032) Table 41. Global Virus Like Particles Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Virus Like Particles Revenue by Application (2021-2026) & (K Units) Table 43. Global Virus Like Particles Revenue by Application (2027-2032) & (K Units) Table 44. Global Virus Like Particles Revenue Market Share by Application (2021-2026) Table 45. Global Virus Like Particles Revenue Market Share by Application (2027-2032) Table 46. Global Virus Like Particles Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Virus Like Particles Sales by Region (2021-2026) & (K Units) Table 48. Global Virus Like Particles Sales Market Share by Region (2021-2026) Table 49. Global Virus Like Particles Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Virus Like Particles Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 53. North America Virus Like Particles Sales by Country (2027-2032) & (K Units) Table 54. Europe Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 56. Europe Virus Like Particles Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Virus Like Particles Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Virus Like Particles Sales by Country (2027-2032) & (K Units) Table 63. Global Virus Like Particles Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Virus Like Particles Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Virus Like Particles Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Virus Like Particles Revenue Market Share by Region (2021-2026) Table 67. Global Virus Like Particles Revenue Market Share by Region (2027-2032) Table 68. Agilvax Company Information Table 69. Agilvax Business Overview Table 70. Agilvax Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Agilvax Virus Like Particles Product Portfolio Table 72. Agilvax Recent Development Table 73. Allergy Therapeutics Company Information Table 74. Allergy Therapeutics Business Overview Table 75. Allergy Therapeutics Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Allergy Therapeutics Virus Like Particles Product Portfolio Table 77. Allergy Therapeutics Recent Development Table 78. ANGANY Genetics Company Information Table 79. ANGANY Genetics Business Overview Table 80. ANGANY Genetics Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. ANGANY Genetics Virus Like Particles Product Portfolio Table 82. ANGANY Genetics Recent Development Table 83. CPL Biologicals Company Information Table 84. CPL Biologicals Business Overview Table 85. CPL Biologicals Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. CPL Biologicals Virus Like Particles Product Portfolio Table 87. CPL Biologicals Recent Development Table 88. Cytos Biotechnology Company Information Table 89. Cytos Biotechnology Business Overview Table 90. Cytos Biotechnology Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cytos Biotechnology Virus Like Particles Product Portfolio Table 92. Cytos Biotechnology Recent Development Table 93. GeoVax Labs Company Information Table 94. GeoVax Labs Business Overview Table 95. GeoVax Labs Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. GeoVax Labs Virus Like Particles Product Portfolio Table 97. GeoVax Labs Recent Development Table 98. Medicago Company Information Table 99. Medicago Business Overview Table 100. Medicago Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Medicago Virus Like Particles Product Portfolio Table 102. Medicago Recent Development Table 103. MedImmune Company Information Table 104. MedImmune Business Overview Table 105. MedImmune Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. MedImmune Virus Like Particles Product Portfolio Table 107. MedImmune Recent Development Table 108. Novavax Company Information Table 109. Novavax Business Overview Table 110. Novavax Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Novavax Virus Like Particles Product Portfolio Table 112. Novavax Recent Development Table 113. Serum Institute of India Company Information Table 114. Serum Institute of India Business Overview Table 115. Serum Institute of India Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Serum Institute of India Virus Like Particles Product Portfolio Table 117. Serum Institute of India Recent Development Table 118. TechnoVax Company Information Table 119. TechnoVax Business Overview Table 120. TechnoVax Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. TechnoVax Virus Like Particles Product Portfolio Table 122. TechnoVax Recent Development Table 123. Xiamen Innovax Biotech Company Information Table 124. Xiamen Innovax Biotech Business Overview Table 125. Xiamen Innovax Biotech Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Xiamen Innovax Biotech Virus Like Particles Product Portfolio Table 127. Xiamen Innovax Biotech Recent Development Table 128. GlaxoSmithKline Company Information Table 129. GlaxoSmithKline Business Overview Table 130. GlaxoSmithKline Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. GlaxoSmithKline Virus Like Particles Product Portfolio Table 132. GlaxoSmithKline Recent Development Table 133. Merck Company Information Table 134. Merck Business Overview Table 135. Merck Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Merck Virus Like Particles Product Portfolio Table 137. Merck Recent Development Table 138. Takeda Company Information Table 139. Takeda Business Overview Table 140. Takeda Virus Like Particles Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Takeda Virus Like Particles Product Portfolio Table 142. Takeda Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Virus Like Particles Distributors List Table 146. Virus Like Particles Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Virus Like Particles Product Image Figure 2. Global Virus Like Particles Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Virus Like Particles Market Size (2021-2032) & (US$ Million) Figure 4. Global Virus Like Particles Sales (2021-2032) & (K Units) Figure 5. Global Virus Like Particles Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Virus Like Particles Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Hepatitis B Virus Image Figure 9. Adeno-Associated Virus Image Figure 10. Hepatitis C Virus Image Figure 11. HIV Image Figure 12. Others Image Figure 13. Global Virus Like Particles Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Virus Like Particles Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Virus Like Particles Sales Market Share by Type (2021-2032) Figure 16. Global Virus Like Particles Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Virus Like Particles Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Virus Like Particles Revenue Market Share by Type (2021-2032) Figure 19. Therapeutic and Imaging Agents Image Figure 20. Mycoviruses Image Figure 21. Vaccines Image Figure 22. Virus Research Image Figure 23. Others Image Figure 24. Global Virus Like Particles Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Virus Like Particles Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Virus Like Particles Sales Market Share by Application (2021-2032) Figure 27. Global Virus Like Particles Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Virus Like Particles Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Virus Like Particles Revenue Market Share by Application (2021-2032) Figure 30. North America Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Virus Like Particles Sales Market Share by Country (2021-2032) Figure 32. U.S. Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Virus Like Particles Sales Market Share by Country (2021-2032) Figure 37. Germany Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Virus Like Particles Sales Market Share by Country (2021-2032) Figure 44. China Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Virus Like Particles Sales Market Share by Country (2021-2032) Figure 52. Brazil Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Virus Like Particles Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Virus Like Particles Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Virus Like Particles Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Virus Like Particles Revenue (2021-2032) & (US$ Million) Figure 63. North America Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Virus Like Particles Revenue (2021-2032) & (US$ Million) Figure 65. Europe Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Virus Like Particles Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Virus Like Particles Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Virus Like Particles Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Virus Like Particles Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Virus
  • Adeno-Associated Virus
  • Hepatitis C Virus
  • HIV
  • Others
Applications
  • Therapeutic and Imaging Agents
  • Mycoviruses
  • Vaccines
  • Virus Research
  • Others
Companies covered
  • Agilvax
  • Allergy Therapeutics
  • ANGANY Genetics
  • CPL Biologicals
  • Cytos Biotechnology
  • GeoVax Labs
  • Medicago
  • MedImmune
  • Novavax
  • Serum Institute of India
  • TechnoVax
  • Xiamen Innovax Biotech
  • GlaxoSmithKline
  • Merck
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Virus Like Particles Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Virus Like Particles Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Virus Like Particles Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Virus Like Particles Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Virus Like Particles Market Dynamics
  1. 2.1 Virus Like Particles Industry Trends
  2. 2.2 Virus Like Particles Industry Drivers
  3. 2.3 Virus Like Particles Industry Opportunities and Challenges
  4. 2.4 Virus Like Particles Industry Restraints
3 Virus Like Particles Market by Manufacturers
  1. 3.1 Global Virus Like Particles Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Virus Like Particles Sales by Manufacturers (2021-2026)
  3. 3.3 Global Virus Like Particles Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Virus Like Particles Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Virus Like Particles Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Virus Like Particles Manufacturers, Product Type & Application
  7. 3.7 Global Virus Like Particles Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Virus Like Particles Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Virus Like Particles Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Virus Like Particles Tier 1, Tier 2, and Tier 3
4 Virus Like Particles Market by Type
  1. 4.1 Virus Like Particles Type Introduction
  2. 4.1.1 Hepatitis B Virus
  3. 4.1.2 Adeno-Associated Virus
  4. 4.1.3 Hepatitis C Virus
  5. 4.1.4 HIV
  6. 4.1.5 Others
  7. 4.2 Global Virus Like Particles Sales by Type
  8. 4.2.1 Global Virus Like Particles Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Virus Like Particles Sales by Type (2021-2032)
  10. 4.2.3 Global Virus Like Particles Sales Market Share by Type (2021-2032)
  11. 4.3 Global Virus Like Particles Revenue by Type
  12. 4.3.1 Global Virus Like Particles Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Virus Like Particles Revenue by Type (2021-2032)
  14. 4.3.3 Global Virus Like Particles Revenue Market Share by Type (2021-2032)
5 Virus Like Particles Market by Application
  1. 5.1 Virus Like Particles Application Introduction
  2. 5.1.1 Therapeutic and Imaging Agents
  3. 5.1.2 Mycoviruses
  4. 5.1.3 Vaccines
  5. 5.1.4 Virus Research
  6. 5.1.5 Others
  7. 5.2 Global Virus Like Particles Sales by Application
  8. 5.2.1 Global Virus Like Particles Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Virus Like Particles Sales by Application (2021-2032)
  10. 5.2.3 Global Virus Like Particles Sales Market Share by Application (2021-2032)
  11. 5.3 Global Virus Like Particles Revenue by Application
  12. 5.3.1 Global Virus Like Particles Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Virus Like Particles Revenue by Application (2021-2032)
  14. 5.3.3 Global Virus Like Particles Revenue Market Share by Application (2021-2032)
6 Global Virus Like Particles Sales by Region
  1. 6.1 Global Virus Like Particles Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Virus Like Particles Sales by Region (2021-2032)
  3. 6.2.1 Global Virus Like Particles Sales by Region (2021-2026)
  4. 6.2.2 Global Virus Like Particles Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Virus Like Particles Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Virus Like Particles Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Virus Like Particles Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Virus Like Particles Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Virus Like Particles Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Virus Like Particles Revenue by Region
  1. 7.1 Global Virus Like Particles Revenue by Region
  2. 7.1.1 Global Virus Like Particles Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Virus Like Particles Revenue by Region (2021-2026)
  4. 7.1.3 Global Virus Like Particles Revenue by Region (2027-2032)
  5. 7.1.4 Global Virus Like Particles Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Virus Like Particles Revenue (2021-2032)
  8. 7.2.2 North America Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Virus Like Particles Revenue (2021-2032)
  11. 7.3.2 Europe Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Virus Like Particles Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Virus Like Particles Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Virus Like Particles Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilvax
  2. 8.1.1 Agilvax Company Information
  3. 8.1.2 Agilvax Business Overview
  4. 8.1.3 Agilvax Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilvax Virus Like Particles Product Portfolio
  6. 8.1.5 Agilvax Recent Developments
  7. 8.2 Allergy Therapeutics
  8. 8.2.1 Allergy Therapeutics Company Information
  9. 8.2.2 Allergy Therapeutics Business Overview
  10. 8.2.3 Allergy Therapeutics Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergy Therapeutics Virus Like Particles Product Portfolio
  12. 8.2.5 Allergy Therapeutics Recent Developments
  13. 8.3 ANGANY Genetics
  14. 8.3.1 ANGANY Genetics Company Information
  15. 8.3.2 ANGANY Genetics Business Overview
  16. 8.3.3 ANGANY Genetics Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ANGANY Genetics Virus Like Particles Product Portfolio
  18. 8.3.5 ANGANY Genetics Recent Developments
  19. 8.4 CPL Biologicals
  20. 8.4.1 CPL Biologicals Company Information
  21. 8.4.2 CPL Biologicals Business Overview
  22. 8.4.3 CPL Biologicals Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CPL Biologicals Virus Like Particles Product Portfolio
  24. 8.4.5 CPL Biologicals Recent Developments
  25. 8.5 Cytos Biotechnology
  26. 8.5.1 Cytos Biotechnology Company Information
  27. 8.5.2 Cytos Biotechnology Business Overview
  28. 8.5.3 Cytos Biotechnology Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cytos Biotechnology Virus Like Particles Product Portfolio
  30. 8.5.5 Cytos Biotechnology Recent Developments
  31. 8.6 GeoVax Labs
  32. 8.6.1 GeoVax Labs Company Information
  33. 8.6.2 GeoVax Labs Business Overview
  34. 8.6.3 GeoVax Labs Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GeoVax Labs Virus Like Particles Product Portfolio
  36. 8.6.5 GeoVax Labs Recent Developments
  37. 8.7 Medicago
  38. 8.7.1 Medicago Company Information
  39. 8.7.2 Medicago Business Overview
  40. 8.7.3 Medicago Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Medicago Virus Like Particles Product Portfolio
  42. 8.7.5 Medicago Recent Developments
  43. 8.8 MedImmune
  44. 8.8.1 MedImmune Company Information
  45. 8.8.2 MedImmune Business Overview
  46. 8.8.3 MedImmune Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MedImmune Virus Like Particles Product Portfolio
  48. 8.8.5 MedImmune Recent Developments
  49. 8.9 Novavax
  50. 8.9.1 Novavax Company Information
  51. 8.9.2 Novavax Business Overview
  52. 8.9.3 Novavax Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novavax Virus Like Particles Product Portfolio
  54. 8.9.5 Novavax Recent Developments
  55. 8.10 Serum Institute of India
  56. 8.10.1 Serum Institute of India Company Information
  57. 8.10.2 Serum Institute of India Business Overview
  58. 8.10.3 Serum Institute of India Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Virus Like Particles Product Portfolio
  60. 8.10.5 Serum Institute of India Recent Developments
  61. 8.11 TechnoVax
  62. 8.11.1 TechnoVax Company Information
  63. 8.11.2 TechnoVax Business Overview
  64. 8.11.3 TechnoVax Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 TechnoVax Virus Like Particles Product Portfolio
  66. 8.11.5 TechnoVax Recent Developments
  67. 8.12 Xiamen Innovax Biotech
  68. 8.12.1 Xiamen Innovax Biotech Company Information
  69. 8.12.2 Xiamen Innovax Biotech Business Overview
  70. 8.12.3 Xiamen Innovax Biotech Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
  72. 8.12.5 Xiamen Innovax Biotech Recent Developments
  73. 8.13 GlaxoSmithKline
  74. 8.13.1 GlaxoSmithKline Company Information
  75. 8.13.2 GlaxoSmithKline Business Overview
  76. 8.13.3 GlaxoSmithKline Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline Virus Like Particles Product Portfolio
  78. 8.13.5 GlaxoSmithKline Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Merck Virus Like Particles Product Portfolio
  84. 8.14.5 Merck Recent Developments
  85. 8.15 Takeda
  86. 8.15.1 Takeda Company Information
  87. 8.15.2 Takeda Business Overview
  88. 8.15.3 Takeda Virus Like Particles Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Takeda Virus Like Particles Product Portfolio
  90. 8.15.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Virus Like Particles Value Chain Analysis
  2. 9.1.1 Virus Like Particles Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Virus Like Particles Production Mode & Process
  6. 9.2 Virus Like Particles Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Virus Like Particles Distributors
  9. 9.2.3 Virus Like Particles Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst